{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:47:10Z","timestamp":1789987630540,"version":"4.0.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40265-025-02267-w","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T02:56:38Z","timestamp":1770087398000},"page":"273-285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nanoencapsulated Sirolimus Plus Pegadricase (NASP) in Uncontrolled Gout: Current Status and Future Directions"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0162-9930","authenticated-orcid":false,"given":"Herbert S. B.","family":"Baraf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1558-1202","authenticated-orcid":false,"given":"Naomi","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4978-4072","authenticated-orcid":false,"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"2267_CR1","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s40265-023-01944-y","volume":"83","author":"R Terkeltaub","year":"2023","unstructured":"Terkeltaub R. Emerging urate-lowering drugs and pharmacologic treatment strategies for gout: a narrative review. Drugs. 2023;83:1501\u201321.","journal-title":"Drugs"},{"key":"2267_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.9501","volume":"6","author":"C Yokose","year":"2023","unstructured":"Yokose C, McCormick N, Lu N, Tanikella S, Lin K, Joshi AD, et al. Trends in prevalence of gout among US Asian adults, 2011-2018. JAMA Netw Open. 2023;6:e239501.","journal-title":"JAMA Netw Open"},{"key":"2267_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282f4eff5","volume":"20","author":"E Fels","year":"2008","unstructured":"Fels E, Sundy JS. Refractory gout: what is it and what to do about it? Curr Opin Rheumatol. 2008;20:198.","journal-title":"Curr Opin Rheumatol"},{"key":"2267_CR4","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1002\/art.23803","volume":"58","author":"NL Edwards","year":"2008","unstructured":"Edwards NL. Treatment-failure gout: a moving target. Arthritis Rheum. 2008;58:2587\u201390.","journal-title":"Arthritis Rheum"},{"key":"2267_CR5","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3899\/jrheum.170806","volume":"45","author":"MM Elfishawi","year":"2018","unstructured":"Elfishawi MM, Zleik N, Kvrgic Z, Michet CJ, Crowson CS, Matteson EL, et al. The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years. J Rheumatol. 2018;45:574\u20139.","journal-title":"J Rheumatol"},{"key":"2267_CR6","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72:744\u201360.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2267_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29\u201342.","journal-title":"Ann Rheum Dis"},{"key":"2267_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40744-020-00260-1","volume":"8","author":"M Francis-Sedlak","year":"2021","unstructured":"Francis-Sedlak M, LaMoreaux B, Padnick-Silver L, Holt RJ, Bello AE. Characteristics, comorbidities, and potential consequences of uncontrolled gout: an insurance-claims database study. Rheumatol Ther. 2021;8:183\u201397.","journal-title":"Rheumatol Ther"},{"key":"2267_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-007214","volume":"5","author":"R Jackson","year":"2015","unstructured":"Jackson R, Shiozawa A, Buysman EK, Altan A, Korrer S, Choi H. Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis. BMJ Open. 2015;5:e007214.","journal-title":"BMJ Open"},{"key":"2267_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13696998.2018.1532904","volume":"22","author":"NM Flores","year":"2019","unstructured":"Flores NM, Nuevo J, Klein AB, Baumgartner S, Morlock R. The economic burden of uncontrolled gout: how controlling gout reduces cost. J Med Econ. 2019;22:1\u20136.","journal-title":"J Med Econ"},{"key":"2267_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/BF00163854","volume":"34","author":"XW Wu","year":"1992","unstructured":"Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol. 1992;34:78\u201384.","journal-title":"J Mol Evol"},{"key":"2267_CR12","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/oxfordjournals.molbev.a004123","volume":"19","author":"M Oda","year":"2002","unstructured":"Oda M, Satta Y, Takenaka O, Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol. 2002;19:640\u201353.","journal-title":"Mol Biol Evol"},{"key":"2267_CR13","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1073\/pnas.1320393111","volume":"111","author":"JT Kratzer","year":"2014","unstructured":"Kratzer JT, Lanaspa MA, Murphy MN, Cicerchi C, Graves CL, Tipton PA, et al. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci USA. 2014;111:3763\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2267_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jare.2017.03.003","volume":"8","author":"R El Ridi","year":"2017","unstructured":"El Ridi R, Tallima H. Physiological functions and pathogenic potential of uric acid: a review. J Adv Res. 2017;8:487\u201393.","journal-title":"J Adv Res"},{"key":"2267_CR15","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41584-023-01006-3","volume":"19","author":"N Schlesinger","year":"2023","unstructured":"Schlesinger N, P\u00e9rez-Ruiz F, Liot\u00e9 F. Mechanisms and rationale for uricase use in patients with gout. Nat Rev Rheumatol. 2023;19:640\u20139.","journal-title":"Nat Rev Rheumatol"},{"key":"2267_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41584-020-00540-8","volume":"17","author":"V Strand","year":"2021","unstructured":"Strand V, Goncalves J, Isaacs JD. Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol. 2021;17:81\u201397.","journal-title":"Nat Rev Rheumatol"},{"key":"2267_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40259-022-00517-x","volume":"36","author":"N Schlesinger","year":"2022","unstructured":"Schlesinger N, Padnick-Silver L, LaMoreaux B. Enhancing the response rate to recombinant uricases in patients with gout. BioDrugs. 2022;36:95\u2013103.","journal-title":"BioDrugs"},{"key":"2267_CR18","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1186\/ar4497","volume":"16","author":"PE Lipsky","year":"2014","unstructured":"Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16:R60.","journal-title":"Arthritis Res Ther"},{"key":"2267_CR19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41467-021-27945-7","volume":"13","author":"E Sands","year":"2022","unstructured":"Sands E, Kivitz A, DeHaan W, Leung SS, Johnston L, Kishimoto TK. Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia. Nat Commun. 2022;13:272.","journal-title":"Nat Commun"},{"key":"2267_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jama.2011.1169","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy JS, Baraf HSB, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306:711\u201320.","journal-title":"JAMA"},{"key":"2267_CR21","unstructured":"US Food and Drug Administration. Krystexxa\u00ae (pegloticase): prescribing information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125293s104lbl.pdf. Accessed 19 Jun 2024."},{"key":"2267_CR22","unstructured":"US Food and Drug Administration. Elitek\u00ae (rasburicase): prescribing information. 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/103946s5083lbl.pdf. Accessed 19 Jun 2024."},{"key":"2267_CR23","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40744-023-00546-0","volume":"10","author":"A Kivitz","year":"2023","unstructured":"Kivitz A, DeHaan W, Azeem R, Park J, Rhodes S, Inshaw J, et al. Phase 2 dose-finding study in patients with gout using SEL-212, a novel PEGylated uricase (SEL-037) combined with tolerogenic nanoparticles (SEL-110). Rheumatol Ther. 2023;10:825\u201347.","journal-title":"Rheumatol Ther"},{"key":"2267_CR24","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/rheumatology\/kead333","volume":"63","author":"HSB Baraf","year":"2024","unstructured":"Baraf HSB, Khanna PP, Kivitz AJ, Strand V, Choi HK, Terkeltaub R, et al. The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR\u2122) versus pegloticase for refractory gout. Rheumatology. 2024;63:1058\u201367.","journal-title":"Rheumatology"},{"key":"2267_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000075","volume":"1","author":"EG Araujo","year":"2015","unstructured":"Araujo EG, Bayat S, Petsch C, Englbrecht M, Faustini F, Kleyer A, et al. Tophus resolution with pegloticase: a prospective dual-energy CT study. RMD Open. 2015;1:e000075.","journal-title":"RMD Open"},{"key":"2267_CR26","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1186\/ar4318","volume":"15","author":"HSB Baraf","year":"2013","unstructured":"Baraf HSB, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD, et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013;15:R137.","journal-title":"Arthritis Res Ther"},{"key":"2267_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/RHU.0000000000000200","volume":"20","author":"HSB Baraf","year":"2014","unstructured":"Baraf HSB, Yood RA, Ottery FD, Sundy JS, Becker MA. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014;20:427\u201332.","journal-title":"J Clin Rheumatol"},{"key":"2267_CR28","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","volume":"26","author":"B Coiffier","year":"2008","unstructured":"Coiffier B, Altman A, Pui C-H, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26:2767\u201378.","journal-title":"J Clin Oncol"},{"key":"2267_CR29","first-page":"2093","volume":"34","author":"P Richette","year":"2007","unstructured":"Richette P, Bri\u00e8re C, Hoenen-Clavert V, Loeuille D, Bardin T. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol. 2007;34:2093\u20138.","journal-title":"J Rheumatol"},{"key":"2267_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.37349\/emd.2024.00070","volume":"2","author":"N Schlesinger","year":"2024","unstructured":"Schlesinger N, Kaufmann D. Uricases: reflections on recent developments in the management of challenging gout patients. Explor Musculoskeletal Dis. 2024;2:461\u201372.","journal-title":"Explor Musculoskeletal Dis"},{"key":"2267_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40264-014-0255-7","volume":"38","author":"KC Allen","year":"2015","unstructured":"Allen KC, Champlain AH, Cotliar JA, Belknap SM, West DP, Mehta J, et al. Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf. 2015;38:183\u20137.","journal-title":"Drug Saf"},{"key":"2267_CR32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.semarthrit.2021.01.005","volume":"51","author":"RT Keenan","year":"2021","unstructured":"Keenan RT, Botson JK, Masri KR, Padnick-Silver L, LaMoreaux B, Albert JA, et al. The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review. Semin Arthritis Rheum. 2021;51:347\u201352.","journal-title":"Semin Arthritis Rheum"},{"key":"2267_CR33","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/acr2.11578","volume":"5","author":"JK Botson","year":"2023","unstructured":"Botson JK, Saag K, Peterson J, Obermeyer K, Xin Y, LaMoreaux B, et al. A randomized, double-blind, placebo-controlled multicenter efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: 12-month findings. ACR Open Rheumatol. 2023;5:407\u201318.","journal-title":"ACR Open Rheumatol"},{"key":"2267_CR34","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/art.41731","volume":"73","author":"PP Khanna","year":"2021","unstructured":"Khanna PP, Khanna D, Cutter G, Foster J, Melnick J, Jaafar S, et al. Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2021;73:1523\u201332.","journal-title":"Arthritis Rheum"},{"key":"2267_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14993","volume":"37","author":"A Abdellatif","year":"2023","unstructured":"Abdellatif A, Zhao L, Chamberlain J, Cherny K, Xin Y, Marder BA, et al. Pegloticase efficacy and safety in kidney transplant recipients; results of the phase IV, open-label PROTECT clinical trial. Clin Transplant. 2023;37:e14993.","journal-title":"Clin Transplant"},{"key":"2267_CR36","volume":"14","author":"KM Hamed","year":"2022","unstructured":"Hamed KM, Dighriri IM, Baomar AF, Alharthy BT, Alenazi FE, Alali GH, et al. Overview of methotrexate toxicity: a comprehensive literature review. Cureus. 2022;14:e29518.","journal-title":"Cureus."},{"key":"2267_CR37","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fimmu.2018.00230","volume":"9","author":"TK Kishimoto","year":"2018","unstructured":"Kishimoto TK, Maldonado RA. Nanoparticles for the induction of antigen-specific immunological tolerance. Front Immunol. 2018;9:230.","journal-title":"Front Immunol"},{"key":"2267_CR38","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/nnano.2016.135","volume":"11","author":"TK Kishimoto","year":"2016","unstructured":"Kishimoto TK, Ferrari JD, LaMothe RA, Kolte PN, Griset AP, O\u2019Neil C, et al. Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles. Nat Nanotechnol. 2016;11:890\u20139.","journal-title":"Nat Nanotechnol"},{"issue":"11","key":"2267_CR39","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3389\/fimmu.2020.00969","volume":"20","author":"TK Kishimoto","year":"2020","unstructured":"Kishimoto TK. Development of ImmTOR tolerogenic nanoparticles for the mitigation of anti-drug antibodies. Front Immunol. 2020;20(11):969.","journal-title":"Front Immunol"},{"key":"2267_CR40","first-page":"279","volume":"22","author":"PO Ilyinskii","year":"2021","unstructured":"Ilyinskii PO, Michaud AM, Rizzo GL, Roy CJ, Leung SS, Elkins SL, et al. ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia. Mol Ther. 2021;22:279\u201392.","journal-title":"Mol Ther"},{"key":"2267_CR41","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","volume":"14","author":"J Klawitter","year":"2015","unstructured":"Klawitter J, Nashan B, Christians U. Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf. 2015;14:1055\u201370.","journal-title":"Expert Opin Drug Saf"},{"key":"2267_CR42","first-page":"1942","volume":"29","author":"JS Bomalaski","year":"2002","unstructured":"Bomalaski JS, Holtsberg FW, Ensor CM, Clark MA. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol. 2002;29:1942\u20139.","journal-title":"J Rheumatol"},{"key":"2267_CR43","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1182\/blood.V114.22.3086.3086","volume":"114","author":"Z Zhang","year":"2009","unstructured":"Zhang Z, Fiorino A. Pharmacokinetics of intravenous uricase-PEG 20, a drug for managing hyperuricemia in tumor lysis syndrome. Blood. 2009;114:3086.","journal-title":"Blood"},{"key":"2267_CR44","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41577-023-00970-x","volume":"24","author":"JE Kenison","year":"2024","unstructured":"Kenison JE, Stevens NA, Quintana FJ. Therapeutic induction of antigen-specific immune tolerance. Nat Rev Immunol. 2024;24:338\u201357.","journal-title":"Nat Rev Immunol"},{"key":"2267_CR45","doi-asserted-by":"publisher","first-page":"E733","DOI":"10.1073\/pnas.1717063115","volume":"115","author":"R Mazor","year":"2018","unstructured":"Mazor R, King EM, Onda M, Cuburu N, Addissie S, Crown D, et al. Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity. Proc Natl Acad Sci U S A. 2018;115:E733\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2267_CR46","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.it.2015.05.007","volume":"36","author":"DR Getts","year":"2015","unstructured":"Getts DR, Shea LD, Miller SD, King NJC. Harnessing nanoparticles for immune modulation. Trends Immunol. 2015;36:419\u201327.","journal-title":"Trends Immunol"},{"key":"2267_CR47","doi-asserted-by":"publisher","first-page":"E156","DOI":"10.1073\/pnas.1408686111","volume":"112","author":"RA Maldonado","year":"2015","unstructured":"Maldonado RA, LaMothe RA, Ferrari JD, Zhang A-H, Rossi RJ, Kolte PN, et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci USA. 2015;112:E156\u201365.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2267_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637469","volume":"12","author":"PO Ilyinskii","year":"2021","unstructured":"Ilyinskii PO, Roy CJ, LePrevost J, Rizzo GL, Kishimoto TK. Enhancement of the tolerogenic phenotype in the liver by ImmTOR nanoparticles. Front Immunol. 2021;12:637469.","journal-title":"Front Immunol"},{"key":"2267_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.33","volume":"2","author":"C Emoto","year":"2013","unstructured":"Emoto C, Fukuda T, Cox S, Christians U, Vinks A. Development of a physiologically-based pharmacokinetic model for sirolimus: predicting bioavailability based on intestinal CYP3A content. CPT Pharmacometrics Syst Pharmacol. 2013;2:59.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2267_CR50","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza AS, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther. 2023;8:375.","journal-title":"Signal Transduct Target Ther"},{"key":"2267_CR51","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.2217\/imt.14.84","volume":"6","author":"NM Chapman","year":"2014","unstructured":"Chapman NM, Chi H. mTOR signaling, Tregs and immune modulation. Immunotherapy. 2014;6:1295\u2013311.","journal-title":"Immunotherapy"},{"key":"2267_CR52","doi-asserted-by":"publisher","unstructured":"Fischer R, Turnquist HR Taner T Thomason AW. Use of rapamycin in the induction of tolerogenic dendritic cells. In: Lombardi G, Riffo-Vasquez Y, editors. Dendritic Cells. Handbook of Experimental Pharmacology, Springer: Berlin, Heidelberg. 2009;188:215\u201332. https:\/\/doi.org\/10.1007\/978-3-540-71029-5_10","DOI":"10.1007\/978-3-540-71029-5_10"},{"issue":"9","key":"2267_CR53","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3389\/fimmu.2018.00281","volume":"2","author":"RA LaMothe","year":"2018","unstructured":"LaMothe RA, Kolte PN, Vo T, Ferrari JD, Gelsinger TC, Wong J, et al. Tolerogenic nanoparticles induce antigen-specific regulatory T cells and provide therapeutic efficacy and transferrable tolerance against experimental autoimmune encephalomyelitis. Front Immunol. 2018;2(9):281.","journal-title":"Front Immunol"},{"key":"2267_CR54","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","volume":"9","author":"A Meliani","year":"2018","unstructured":"Meliani A, Boisgerault F, Hardet R, Marmier S, Collaud F, Ronzitti G, et al. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat Commun. 2018;9:4098.","journal-title":"Nat Commun"},{"key":"2267_CR55","first-page":"18","volume":"13","author":"H-H Lim","year":"2017","unstructured":"Lim H-H, Yi H, Kishimoto TK, Gao F, Sun B, Kishnani PS. A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease. Mol Genet Metab Rep. 2017;13:18\u201322.","journal-title":"Mol Genet Metab Rep"},{"key":"2267_CR56","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/annrheumdis-2024-eular.2832","volume":"83","author":"HSB Baraf","year":"2024","unstructured":"Baraf HSB, Khanna P, Patel A, Singhal A, Sobierska J, Santin-Janin H, et al. POS0260 Once-monthly SEL-212 demonstrates efficacy and safety for up to 6 months in gout refractory to conventional therapy: combined data from the DISSOLVE I and II phase 3, double blind, placebo-controlled clinical trials. Ann Rheum Dis. 2024;83:408\u20139.","journal-title":"Ann Rheum Dis"},{"key":"2267_CR57","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.202457c52mh7","volume":"35","author":"P Khanna","year":"2024","unstructured":"Khanna P, Johnson RJ, Azeem R, Falk A, Desai B, Santin-Janin H, et al. Efficacy and safety of SEL-212 in patients with refractory gout and CKD: a post hoc analysis from the two phase 3 DISSOLVE studies: TH-PO1075. J Am Soc Nephrol. 2024;35:10.","journal-title":"J Am Soc Nephrol"},{"key":"2267_CR58","unstructured":"Strand V, Khanna P, Kivitz A, Kragh N, Falk A, Azeem R, et al. Improvements in patient-reported outcomes after treatment with SEL-212 in adults with refractory gout: results from two randomized phase 3 trials [abstract]. Arthritis Rheumatol. 2024;76(suppl 9)."},{"key":"2267_CR59","unstructured":"Pillinger M, Kivitz A, Singhal A, Patel A, Azeem R, Falk A, et al. Safety and efficacy of SEL-212 in the US and ex-US subgroups: results from the phase 3 DISSOLVE studies [abstract]. Arthritis Rheumatol. 2024;76(suppl 9)."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02267-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02267-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02267-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:31:07Z","timestamp":1772771467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02267-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2267"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02267-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Herbert S.B. Baraf: Arthrosi, Olatec, Sobi, Otsuka, Pacira. Naomi Schlesinger: Amgen, Arthrosi, Novartis, Olatec, Protalix, Shanton, Sobi, Scilex, Avalo. Vibeke Strand: AbbVie, Alpine, Alumis, Amgen, AstraZenecaBayer, Blackrock, BMS, Boehringer Ingelheim, Celltrion, Citryll, Contura, Fortress Biotech, Genentech\/Roche, GSK, Inmedix, Janssen, Kiniksa, Lilly, Novartis, Omeros, Pfizer, RAPT, Regeneron, R-Pharm, Samsung, Sandoz, Sanofi, Scipher, Setpoint, Sobi, Spherix, Synact, Takeda, Urica, Vertex.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This extended review presents information from phase I\u2013III clinical studies of NASP. All study protocols were approved by an ethics committee or institutional review board at each participating center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets analyzed during the current study are available from the corresponding author on reasonable request. Sobi is committed to responsible and ethical sharing of data on the participant-level and summary data for medicines and indications approved by the European Medicines Agency and\/or FDA, while protecting individual participant integrity and compliance with applicable legislation. Data access will be granted in response to qualified research requests. All requests are evaluated by a cross\u2010functional panel of experts within Sobi, and a decision on sharing will be based on the scientific merit and feasibility of the research proposal, maintenance of personal integrity, and commitment to publication of the results. To request access to study data, a data-sharing request form (available on\n                      \n                      ) should be sent to medical.info@sobi.com. Further information on Sobi\u2019s data sharing policy and process for requesting access can be found at:\n                      \n                      .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors meet the International Committee of Medical Journal Editors\u2019 criteria for authorship for this article. All authors were responsible for manuscript conceptualization, writing the original draft, and reviewing and editing the final manuscript draft. All authors take responsibility for the manuscript as a whole and have given their approval for this version to be published.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}